Skip to main navigation Skip to search Skip to main content

Targeting the hedgehog pathway for locally advanced and metastatic basal cell carcinoma

  • Vivian T. Yin
  • , Bita Esmaeli

Research output: Contribution to journal › Article › peer-review

Abstract

Basal cell caricnoma (BCC), the most common periocular magliancy, is treated with complete surgical excision. However, in patients not amenable to surgery or when surgical resection means loss of vital organs or disfiguring procedures due to locally advanced or metastatic disease, targeting the hedgehog pathway offers a novel treatment approach for such patients. Mutation in PTCH1 and SMO has been identified in patients with basal cell nevoid syndrome as well as in patients with sporadic BCC. Inhibition of SMO by vismodegib or sonidegib, the two sonic hedgehog inhibitor drugs approved by the Food and Drug Administration in the United States, has shown overall response rate for locally advanced and metastatic BCC around 50%. The most common side effects were muscle cramps, weight loss, fatigue, and lost appetite. Resistance to vismodegib has been attributed to mutation in SMO or activation of RAS/MAPK pathway. New research into dual inhibition aims to overcome this resistance and provide more lasting response.

Original languageEnglish (US)
Pages (from-to)655-659
Number of pages5
JournalCurrent pharmaceutical design
Volume23
Issue number4
DOIs
StatePublished - Feb 1 2017

Keywords

  • Basal cell carcinoma
  • Hedgehog inhibitors
  • Hedgehog pathway
  • Locally advanced BCC
  • Sonidegib
  • Targeted therapy
  • Vismodegib

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint

Dive into the research topics of 'Targeting the hedgehog pathway for locally advanced and metastatic basal cell carcinoma'. Together they form a unique fingerprint.

Cite this